309 related articles for article (PubMed ID: 29348486)
41. A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: a study of the National Cancer Institute of Canada Clinical Trials Group.
Goss G; Shepherd FA; Laurie S; Gauthier I; Leighl N; Chen E; Feld R; Powers J; Seymour L
Eur J Cancer; 2009 Mar; 45(5):782-8. PubMed ID: 19091548
[TBL] [Abstract][Full Text] [Related]
42. A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study.
Santoro A; Gebbia V; Pressiani T; Testa A; Personeni N; Arrivas Bajardi E; Foa P; Buonadonna A; Bencardino K; Barone C; Ferrari D; Zaniboni A; Tronconi MC; Cartenì G; Milella M; Comandone A; Ferrari S; Rimassa L
Ann Oncol; 2015 Mar; 26(3):542-7. PubMed ID: 25538178
[TBL] [Abstract][Full Text] [Related]
43. Phase I trial of S-1 every other day in combination with gemcitabine/cisplatin for inoperable biliary tract cancer.
Uwagawa T; Sakamoto T; Abe K; Okui N; Hata D; Shiba H; Futagawa Y; Aiba K; Yanaga K
Cancer Chemother Pharmacol; 2015 Jan; 75(1):191-6. PubMed ID: 25422155
[TBL] [Abstract][Full Text] [Related]
44. Phase II study of liposomal cisplatin (Lipoplatin) plus gemcitabine versus cisplatin plus gemcitabine as first line treatment in inoperable (stage IIIB/IV) non-small cell lung cancer.
Mylonakis N; Athanasiou A; Ziras N; Angel J; Rapti A; Lampaki S; Politis N; Karanikas C; Kosmas C
Lung Cancer; 2010 May; 68(2):240-7. PubMed ID: 19628292
[TBL] [Abstract][Full Text] [Related]
45. Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas.
Ko AH; Espinoza AM; Jones KA; Venook AP; Bergsland EK; Kelley RK; Dito E; Ong A; Hanover CS; Coakley FV; Tempero MA
Am J Clin Oncol; 2012 Oct; 35(5):411-7. PubMed ID: 21552099
[TBL] [Abstract][Full Text] [Related]
46. Phase I trial of oral S-1 combined with hepatic arterial infusion of gemcitabine in unresectable biliary tract cancer.
Ishiwatari H; Hayashi T; Yoshida M; Ono M; Sato T; Miyanishi K; Sato Y; Takimoto R; Kobune M; Kato J
Cancer Chemother Pharmacol; 2015 Apr; 75(4):805-12. PubMed ID: 25687990
[TBL] [Abstract][Full Text] [Related]
47. Phase I Trial of DNA Methyltransferase Inhibitor Guadecitabine Combined with Cisplatin and Gemcitabine for Solid Malignancies Including Urothelial Carcinoma (SPIRE).
Crabb SJ; Danson S; Catto JWF; Hussain S; Chan D; Dunkley D; Downs N; Marwood E; Day L; Saunders G; Light M; Whitehead A; Ellis D; Sarwar N; Enting D; Birtle A; Johnson B; Huddart R; Griffiths G
Clin Cancer Res; 2021 Apr; 27(7):1882-1892. PubMed ID: 33472913
[TBL] [Abstract][Full Text] [Related]
48. Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors.
Italiano A; Infante JR; Shapiro GI; Moore KN; LoRusso PM; Hamilton E; Cousin S; Toulmonde M; Postel-Vinay S; Tolaney S; Blackwood EM; Mahrus S; Peale FV; Lu X; Moein A; Epler J; DuPree K; Tagen M; Murray ER; Schutzman JL; Lauchle JO; Hollebecque A; Soria JC
Ann Oncol; 2018 May; 29(5):1304-1311. PubMed ID: 29788155
[TBL] [Abstract][Full Text] [Related]
49. Phase I trial of everolimus, gemcitabine and cisplatin in patients with solid tumors.
Costello BA; Borad MJ; Qi Y; Kim GP; Northfelt DW; Erlichman C; Alberts SR
Invest New Drugs; 2014 Aug; 32(4):710-6. PubMed ID: 24740268
[TBL] [Abstract][Full Text] [Related]
50. A Phase II Study of Biweekly Cisplatin, Fixed-Dose-Rate Gemcitabine and Infusional 5-Fluorouracil in Patients With Metastatic Pancreatic and Biliary Cancers.
Davis EJ; Griffith KA; Kim EJ; Ruch JM; McDonnell KJ; Zalupski MM
Am J Clin Oncol; 2018 Feb; 41(2):128-132. PubMed ID: 26535993
[TBL] [Abstract][Full Text] [Related]
51. Feasibility of Combining the Phosphatidylinositol 3-Kinase Inhibitor Copanlisib With Rituximab-Based Immunochemotherapy in Patients With Relapsed Indolent B-cell Lymphoma.
Matasar MJ; Dreyling M; Leppä S; Santoro A; Pedersen M; Buvaylo V; Fletcher M; Childs BH; Zinzani PL
Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):e886-e894. PubMed ID: 34389273
[TBL] [Abstract][Full Text] [Related]
52. Combination treatment of copanlisib and gemcitabine in relapsed/refractory PTCL (COSMOS): an open-label phase I/II trial.
Yhim HY; Kim T; Kim SJ; Shin HJ; Koh Y; Kim JS; Park J; Park GS; Kim WS; Moon JH; Yang DH
Ann Oncol; 2021 Apr; 32(4):552-559. PubMed ID: 33352201
[TBL] [Abstract][Full Text] [Related]
53. Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: a phase I dose-escalation study.
Reck M; Frickhofen N; Cedres S; Gatzemeier U; Heigener D; Fuhr HG; Thall A; Lanzalone S; Stephenson P; Ruiz-Garcia A; Chao R; Felip E
Lung Cancer; 2010 Nov; 70(2):180-7. PubMed ID: 20188433
[TBL] [Abstract][Full Text] [Related]
54. A parallel dose-escalation study of weekly and twice-weekly bortezomib in combination with gemcitabine and cisplatin in the first-line treatment of patients with advanced solid tumors.
Voortman J; Smit EF; Honeywell R; Kuenen BC; Peters GJ; van de Velde H; Giaccone G
Clin Cancer Res; 2007 Jun; 13(12):3642-51. PubMed ID: 17575229
[TBL] [Abstract][Full Text] [Related]
55. Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study.
Kotasek D; Tebbutt N; Desai J; Welch S; Siu LL; McCoy S; Sun YN; Johnson J; Adewoye AH; Price T
BMC Cancer; 2011 Jul; 11():313. PubMed ID: 21791058
[TBL] [Abstract][Full Text] [Related]
56. Comparison of gemcitabine plus cisplatin versus capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer.
Park K; Kim KP; Park S; Chang HM
Asia Pac J Clin Oncol; 2017 Feb; 13(1):13-20. PubMed ID: 27770489
[TBL] [Abstract][Full Text] [Related]
57. Phase I/II study of mocetinostat in combination with gemcitabine for patients with advanced pancreatic cancer and other advanced solid tumors.
Chan E; Chiorean EG; O'Dwyer PJ; Gabrail NY; Alcindor T; Potvin D; Chao R; Hurwitz H
Cancer Chemother Pharmacol; 2018 Feb; 81(2):355-364. PubMed ID: 29238851
[TBL] [Abstract][Full Text] [Related]
58. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial.
Gatzemeier U; Pluzanska A; Szczesna A; Kaukel E; Roubec J; De Rosa F; Milanowski J; Karnicka-Mlodkowski H; Pesek M; Serwatowski P; Ramlau R; Janaskova T; Vansteenkiste J; Strausz J; Manikhas GM; Von Pawel J
J Clin Oncol; 2007 Apr; 25(12):1545-52. PubMed ID: 17442998
[TBL] [Abstract][Full Text] [Related]
59. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial.
Malka D; Cervera P; Foulon S; Trarbach T; de la Fouchardière C; Boucher E; Fartoux L; Faivre S; Blanc JF; Viret F; Assenat E; Seufferlein T; Herrmann T; Grenier J; Hammel P; Dollinger M; André T; Hahn P; Heinemann V; Rousseau V; Ducreux M; Pignon JP; Wendum D; Rosmorduc O; Greten TF;
Lancet Oncol; 2014 Jul; 15(8):819-28. PubMed ID: 24852116
[TBL] [Abstract][Full Text] [Related]
60. A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.
O'Neil BH; Scott AJ; Ma WW; Cohen SJ; Aisner DL; Menter AR; Tejani MA; Cho JK; Granfortuna J; Coveler L; Olowokure OO; Baranda JC; Cusnir M; Phillip P; Boles J; Nazemzadeh R; Rarick M; Cohen DJ; Radford J; Fehrenbacher L; Bajaj R; Bathini V; Fanta P; Berlin J; McRee AJ; Maguire R; Wilhelm F; Maniar M; Jimeno A; Gomes CL; Messersmith WA
Ann Oncol; 2015 Sep; 26(9):1923-1929. PubMed ID: 26091808
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
